Comment on “Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients”

We read with interest the real-world study by Okazaki et al. comparing ritlecitinib outcomes between JAK inhibitor (JAKi)–naïve and JAKi-experienced patients with alopecia areata (AA) [1]. Their results provide important clinical confirmation of an emerging trend: response to a second JAKi is substantially reduced among patients who did not respond to a prior agent. While the JAKi-naïve cohort achieved a SALT50 response rate of 100% (9/9) at week 24, only 23% (3/13) of the JAKi-experienced group reached the same threshold [1]. This notable difference highlights a therapeutic challenge that extends beyond the pharmacological profile of individual drugs and points toward an underlying pathophysiological mechanism. We propose that the attenuated response to sequential JAKi therapy reflects the convergence of progressive disease dynamics and agent-specific pharmacological properties. First, patients in the JAKi-experienced cohort reported by Okazaki et al. exhibited a substantially longer median duration of their current alopecia areata episode (68 vs. 20 months) [1]. Prolonged inflammation may drive immune pathway redundancy, a phenomenon observed in conditions such as hidradenitis suppurativa [2], where chronic disease can activate parallel inflammatory axes (e.g., NF-κB, inflammasome) that maintain disease activity despite blockade of a primary pathway such as JAK–STAT. In AA, sustained inflammation could similarly promote a shift in disease biology beyond the initial therapeutic target. Second, and more specifically, pharmacological differences between JAK1 and JAK3 inhibition help explain the attenuated efficacy observed when switching from baricitinib (JAK1/2 inhibitor) to ritlecitinib (a JAK3/TEC inhibitor). JAK1 is integral to signaling in two central pathways implicated in AA pathogenesis: interferon-gamma (IFN-γ) and the γ-chain family of cytokines (e.g., IL-2, IL-4, IL-7, IL-9, IL-15), which signal through the common cytokine receptor γ-chain [3]. In contrast, JAK3 primarily mediates signaling downstream of these γ-chain cytokines [3]. Baricitinib, by inhibiting JAK1, exerts broad suppression across both the IFN-γ axis and multiple γ-chain cytokine pathways. Disease persistence under this broad inhibition may indicate a shift toward inflammatory drivers less reliant on these pathways. Switching to ritlecitinib—which selectively targets JAK3 and thus modulates γ-chain cytokine signaling while largely sparing JAK1-dependent IFN-γ responses—represents a narrowing of the therapeutic scope that may be inadequate for controlling resistant disease. This mechanistic interpretation leads to a testable clinical hypothesis: the direction of the switch may significantly influence outcomes. Transitioning from a more selective agent (e.g., ritlecitinib) to a JAK1-inhibiting agent with broader activity (such as baricitinib or Ivarmacitinib [4]) may offer a higher likelihood of recapturing clinical response. In this scenario, disease progression during ritlecitinib treatment may reflect predominant reliance on IFN-γ or other JAK1-dependent pathways. Escalating to a JAK1 inhibitor would thus introduce a distinct and broader mechanism of action—notably adding potent IFN-γ blockade—rather than merely overlapping with the previous therapeutic spectrum. In a word, these findings highlight the pressing need for a precision medicine framework in AA. Biomarkers capable of distinguishing IFN-γ-dominant, γ-cytokine-dominant, or JAK-independent disease endotypes are essential to guide initial drug selection and inform rational sequencing strategies. Future trials should consider prospectively comparing the efficacy of different JAKi switch sequences to better guide clinical practice. The author(s) employed DeepSeek (an AI-powered tool) exclusively for linguistic refinement in this paper, including grammar correction, sentence fluency improvement, and vocabulary enhancement. No AI-generated content was used. All intellectual contributions, analysis, and conclusions remain solely the author(s) own work. The final text was thoroughly reviewed and approved by the author(s). The authors have nothing to report. The authors have nothing to report. The authors declare no conflicts of interest. The authors have nothing to report.